Multiplex Assay Kit for Apolipoprotein A1 (APOA1) ,etc. by FLIA (Flow Luminescence Immunoassay) Rattus norvegicus (Rat) Multiplex ELISA

Apo-A1; ApoA-1 Milano; ProapoA-I; Proapolipoprotein A-I; Truncated apolipoprotein A-I

(Note: Up to 8-plex in one testing reaction)

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Multiplex Assay Kit for Apolipoprotein A1 (APOA1) ,etc. by FLIA (Flow Luminescence Immunoassay) Packages (Simulation)
  • Multiplex Assay Kit for Apolipoprotein A1 (APOA1) ,etc. by FLIA (Flow Luminescence Immunoassay) Packages (Simulation)
  • Multiplex Assay Kit for Apolipoprotein A1 (APOA1) ,etc. by FLIA (Flow Luminescence Immunoassay) Results demonstration
  • LMA519Ra.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Apolipoprotein A1 (APOA1) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Apolipoprotein A1 (APOA1) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 84-101 93
EDTA plasma(n=5) 94-104 98
heparin plasma(n=5) 87-96 91

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Apolipoprotein A1 (APOA1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Apolipoprotein A1 (APOA1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Apolipoprotein A1 (APOA1) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 91-98% 86-95% 98-105% 99-105%
EDTA plasma(n=5) 88-99% 87-96% 79-101% 82-101%
heparin plasma(n=5) 91-99% 84-97% 92-105% 95-104%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:APOA1) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

Multiplex Assay Kit for Apolipoprotein A1 (APOA1) ,etc. by FLIA (Flow Luminescence Immunoassay)

Test principle

Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards, and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest. After washing away any unbound substances, a biotinylated antibody cocktail specific to the analytes of interest is added to each well. Following a wash to remove any unbound biotinylated antibody, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE), which binds to the biotinylated detection antibodies, is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer.The MFI developed is proportional to the concentration of analytes of interest in the sample.

Giveaways

Citations

  • Endurance training enhances ABCA1 expression in rat small intestinePubMed: 19629515
  • Effect of eight weeks of wrestling and circuit fitness training on Apo lipoportein A-I and lymphocyte ABCA1 gene expression in well-trained wrestler. Wrestling: source
  • Treadmill exercise enhances ABCA1 expression in rat liverScienceDirect: S0006291X0701488X
  • The Effect of Eight Weeks of Wrestling and Wrestling Technique Based Circuit Training on Lymphocyte ABCA1 Gene Expression and Plasma Apolipoprotein A-1Idosi: source
  • Hepatic lipase- and endothelial lipase-deficiency in mice promotes macrophage-to-feces RCT and HDL antioxidant propertiesPubMed: 23328279
  • The association of a distinct plasma proteomic profile with the cervical high-grade squamous intraepithelial lesion of Uyghur women: a 2D liquid-phase chromatography/mass spectrometry studyPubMed: 22458349
  • MicroRNA-33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE?/? MicePubMed: PMC3540673
  • Apolipoprotein AI Is a Potential Mediator of Remote Ischemic PreconditioningPlosone: Source
  • DYRK1A overexpression decreases plasma lecithin: cholesterol acyltransferase activity and apolipoprotein AI levelsPubmed: 23920041
  • Deficiency of Clusterin Exacerbates High-Fat Diet-Induced Insulin Resistance in Male Mice Pubmed: 24684302
  • Corrective effects of hepatotoxicity by hepatic Dyrk1a gene delivery in mice with intermediate hyperhomocysteinemiaSciencedirect:S2214426915000026
  • Anti-atherogenic properties of high-density lipoproteins in psychiatric patients before and after two months of atypical anti-psychotic therapyPubMed: 26253619
  • Culturing of HepG2 cells with human serum improve their functionality and suitability in studies of lipid metabolismPubMed: 26515253
  • Efficacy of tomato concentrates in mouse models of dyslipidemia and cancerPubMed: 26171234
  • Differentially expressed urinary biomarkers in children with idiopathic nephrotic syndromePubMed: 26351173
  • Apolipoprotein A-I inhibits experimental colitis and colitis-propelled carcinogenesisPubMed: 26279300
  • Apolipoprotein AI inhibits experimental colitis and colitis-propelled carcinogenesisPubmed:26279300
  • Serum levels of 9α,11β-PGF2 and apolipoprotein A1 achieve high predictive power as biomarkers of anaphylaxis.pubmed:28378321
  • Application of a new procedure for liquid chromatography/mass spectrometry profiling of plasma amino acid-related metabolites and untargeted shotgun proteomics to identify mechanisms and biomarkers of calcific aortic stenosisS0021967317311858
  • High-Density Lipoproteins Exert Pro-inflammatory Effects on Macrophages via Passive Cholesterol Depletion and PKC-NF-kB/STAT1-IRF1 Signalingpubmed:27866837
  • Effect of Ginkgo biloba Extract (EGb 761) on Serum Cholesterol Levels in Wild-type C57Bl/6 Mice10.15616/BSL.2017.23.2.80
  • Enhanced Antiatherosclerotic Efficacy of Statin-Loaded Reconstituted High-Density Lipoprotein via Ganglioside GM1 Modificationabs:10.1021
  • Wild Lonicera caerulea berry polyphenol extract reduces cholesterol accumulation and enhances antioxidant capacity in vitro and in vivoPubmed:29580541
  • Consumption of orange fermented beverage improves antioxidant status and reduces peroxidation lipid and inflammatory markers in healthy humansPubmed:29124773
  • A membrane disrupting toxin from wasp venom underlies the molecular mechanism of tissue damagePubmed:29654869
  • The effect of exenatide (a GLP-1 analog) and sitagliptin (a DPP-4 inhibitor) on plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and concentration in?…Pubmed: 30768981
  • High-intensity interval training has a greater effect on reverse cholesterol transport elements compared with moderate-intensity continuous training in obese male ratsPubmed: 31718266
  • Systemic Alterations of Immune Response-Related Proteins during Glaucoma Development in the Murine Model DBA/2JPubmed: 32585848
  • Pathology and Proteomics-Based Diagnosis of Localized Light-Chain Amyloidosis in Dogs and CatsPubmed: 32880234
  • GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity34853313
  • Interplay of Obesity, Ethanol, and Contaminant Mixture on Clinical Profiles of Cardiovascular and Metabolic Diseases: Evidence from an Animal StudyPubmed:35429258
  • Neuropeptide Y promotes hepatic apolipoprotein A1 synthesis and secretion through neuropeptide Y Y5 receptorPubmed:35660638
  • Castanea mollissima shell polyphenols regulate JAK2 and PPARγ expression to suppress inflammation and lipid accumulation by inhibiting M1 macrophages …

Recommend products